Fractalkine: an inflammatory chemokine elevated in subjects with polycystic ovary syndrome.
Body mass index
Fractalkine
Hyperandrogenism
Inflammation
Insulin resistance
Polycystic ovary syndrome
Journal
Endocrine
ISSN: 1559-0100
Titre abrégé: Endocrine
Pays: United States
ID NLM: 9434444
Informations de publication
Date de publication:
07 2019
07 2019
Historique:
received:
15
03
2019
accepted:
25
05
2019
pubmed:
4
6
2019
medline:
30
5
2020
entrez:
3
6
2019
Statut:
ppublish
Résumé
Fractalkine (FKN) is an inflammatory chemokine related to reproductive system and glucose metabolism. There is a link between FKN and steroidogenesis as FKN induces progesterone synthesis. Polycystic ovary syndrome (PCOS) is a common reproductive and metabolic disorder associated with low progesterone production and insulin resistance. We aimed to explore whether women with PCOS have any difference in FKN levels compared to women without PCOS. We also focused on determination of any association between FKN levels and hormonal-metabolic parameters in women with PCOS. The current research was designed as a case-control study. Eighty subjects with PCOS and 80 age- and body mass index (BMI)-matched subjects with normal menstrual cycle were taken into the study. We measured circulating FKN levels via ELISA methods. Circulating FKN levels were higher in women with PCOS than controls (1.93 ± 0.61 vs. 1.22 ± 0.33 ng/ml, P< 0.001). FKN levels showed a positive correlation with body mass index (BMI), insulin resistance, inflammatory marker hs-CRP, total testosterone, and free-androgen index (FAI), whereas it showed a negative correlation with sex hormone-binding protein in women with PCOS. Linear regression analyses revealed that the link of FKN with BMI, insulin resistance, hs-CRP, and FAI was independent. Binary logistic regression analysis showed that the risk of having PCOS was associated with high levels of FKN. Increased FKN levels related to insulin resistance, inflammation and androgens in women with PCOS. FKN may have an inter-related role in different pathophysiologic pathways of PCOS.
Identifiants
pubmed: 31154608
doi: 10.1007/s12020-019-01972-3
pii: 10.1007/s12020-019-01972-3
doi:
Substances chimiques
CX3CL1 protein, human
0
Chemokine CX3CL1
0
Inflammation Mediators
0
Testosterone
3XMK78S47O
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
175-183Références
Obesity (Silver Spring). 2011 Jan;19(1):222-7
pubmed: 20523302
Nature. 1997 Feb 13;385(6617):640-4
pubmed: 9024663
Reprod Biol Endocrinol. 2011 Jun 30;9:95
pubmed: 21718473
J Clin Endocrinol Metab. 1961 Nov;21:1440-7
pubmed: 13892577
J Clin Endocrinol Metab. 2006 Jan;91(1):48-53
pubmed: 16249284
J Immunol. 2000 Apr 15;164(8):4313-20
pubmed: 10754331
Steroids. 2012 Mar 10;77(4):300-5
pubmed: 22178787
Cell. 1997 Nov 14;91(4):521-30
pubmed: 9390561
Sci Rep. 2016 Jul 08;6:26205
pubmed: 27386819
J Leukoc Biol. 1999 Dec;66(6):937-44
pubmed: 10614775
J Diabetes Metab Disord. 2017 Apr 4;16:15
pubmed: 28396851
Cell. 2013 Apr 11;153(2):413-25
pubmed: 23582329
Cardiovasc Pathol. 2002 Nov-Dec;11(6):332-8
pubmed: 12459434
Hum Reprod. 2004 Jan;19(1):41-7
pubmed: 14688154
Diabetes Res Clin Pract. 2006 May;72(2):219-20
pubmed: 16310881
J Clin Invest. 1976 May;57(5):1320-9
pubmed: 770505
Diabetes. 2011 May;60(5):1512-8
pubmed: 21525510
Diabet Med. 2014 Aug;31(8):1014-7
pubmed: 24673545
Clin Chem. 1972 Jun;18(6):499-502
pubmed: 4337382
J Clin Endocrinol Metab. 2004 Jun;89(6):2745-9
pubmed: 15181052
Int J Endocrinol. 2014;2014:232454
pubmed: 24695544
Endocrinology. 2008 Jun;149(6):2782-9
pubmed: 18292196
Hum Reprod. 2010 Feb;25(2):544-51
pubmed: 19910321
N Engl J Med. 2005 Mar 24;352(12):1223-36
pubmed: 15788499
Oman Med J. 2012 Nov;27(6):471-4
pubmed: 23226817
Pediatrics. 2012 May;129(5):e1180-6
pubmed: 22473371
Metabolism. 2013 Aug;62(8):1081-7
pubmed: 23477808
J Endocrinol Invest. 2016 Jul;39(7):747-54
pubmed: 26969461
Endocr Rev. 1997 Dec;18(6):774-800
pubmed: 9408743
Diabetologia. 1985 Jul;28(7):412-9
pubmed: 3899825